Novartis
NOVN
Delayed Swiss Exchange - 09/21 05:30:26 pm
81.88CHF
-0.07%
Prev.81.9400
Open82.5000
High82.5000
Low81.2800
Volume4 419 942
Financials
Sales 2018 52 459 M
EBIT 2018 12 888 M
R. net 2018 11 683 M
Debt 2018 14 565 M
Rend. 2018 3,46%
P/E ratio 2018 14,72
P/E ratio 2019 20,91
EV / Sales 2018 4,40x
EV / Sales 2019 4,24x
Capitalization 216 B
Company
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products.It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate.The Innovative Medicines segment researches, develops, manufactures, distributes and...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-09-26 Presentation
Trading Rating :
Investor Rating :
Latest news
02:42pNOVARTIS : to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
AQ
02:37pNOVARTIS : New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
AQ
01:17pSPARK THERAPEUTICS : Novartis Announces Positive CHMP Opinion for One-Time Gene Therapy Luxturna to Treat Children and Adults With Rare Inherited Retinal Disease
AQ
12:45pSPARK THERAPEUTICS : Novartis Luxturna approved to treat rare retinal disease
AQ
12:45pSPARK THERAPEUTICS : Novartis announces positive CHMP opinion for one-time gene therapy Luxturna to treat children and adults with rare inherited retinal disease
AQ
10:44aSPARK THERAPEUTICS : Novartis drums up EU launch plans as CHMP gives thumbs up to Sparks gene therapy Luxturna
AQ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/21NOVARTIS : uBiome moving into therapeutics with $83M series C
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBullishNeutral
Resistance83,583,587,7
Spread/Res.-1,9%-1,9%-6,7%
Spread/Supp.4,7%4,7%11%
Support78,278,273,9